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Introduction 
Infection remains as the leading cause of morbidity and
mortality after organ transplantation.1) Among them, fungal
infections carry the risk of higher mortality. Candida and
Aspergillus species are the most common fungi that cause
diseases in transplant recipients.2) Especially, Aspergillus most
frequently causes pneumonia and is the opportunistic pathogen
in heart transplant recipients.3) Although invasive aspergillosis
(IA) is a serious disease in heart transplant recipients, little is
known regarding this infection due to limited experience.
Here, we report a lethal case of Aspergillus endocarditis in a
21-year-old male who rapidly deteriorated and died despite
prompt intravenous amphotericin B and antibiotics.
Case
A 21-year-old male suffering from severe dilated cardi-
omyopathy after doxorubicin-based chemotherapy due to
lymphoma underwent heart transplantation in an university
hospital of other country on September 20th, 2006. He was
diagnosed with complete remission of lymphoma after eight
cycles of CHOP regimen (cyclophosphamide, doxorubicin,
vincristine, and prednisone) in 2000. The deceased donor was
a 55-yr-old man without known cardiac disease. According
to the medical records, his initial immunosuppressive regimen
consisted of cyclosporine, mycophenolate mofetil, and
prednisolone. On day 37, he had a seizure attack, followed
by renal impairment due to cyclosporine. He underwent
hemodialysis 3 times a week for 3 weeks. And then, cyclosporine
was changed to FK506. When he was transferred to our
hospital, maintenance immunosuppression consisted of 2
mg of FK506 (target blood trough level 10-20 ng/ml), 2.0 gm
of mycophenolate mofetil, and 10 mg of prednisolone. On
admission, he complained of general weakness. All laboratory
findings were in normal range except for elevated BUN/Cr
level (83.3/2.2 mg/dL), After hydration with intravenous
fluids and reduction of FK506 dosage (1.5 mg/day), the
level of BUN/Cr was normalized. Echocardiography showed
unremarkable with normal left ventricular systolic and
diastolic function. There was no evidence of lymphoma
recurrence on abdominal sonography, computed tomography,
and laboratory data, which was confirmed by a hematologist.
He was discharged 2 weeks later with clinical improvement.
However, he was re-admitted 4 days later with fever, vomiting,
and tachypnea. The leukocyte count was 19.5×103μL
with 83.9% neutrophils, and a mild thrombocytopenia of
110×103μL. On physical examination, body temperature
was 38.6。C and respiratory rate was 40 rate per min. Clear
breathing sounds were noted and he had high blood pressure
䤎Received：May 2, 2007   䤎Accepted：June 4, 2007
䤎Address for Correspondence：Seok-Min Kang, Cardiology Division, Yonsei University College of Medicine, 250 Seongsan-no, Seodaemun-gu, Seoul
120-752, Korea     Tel : +82-2-2228-8450,  Fax : +82-2-393-2041,  E-mail : smkang@yumc.yonsei.ac.kr
Lethal Aspergillus Endocarditis after 
Heart Transplantation
Eun Young Park, MD, Seok-Min Kang, MD, Chan Ho Kim, MD, Dong Hyun Kim, MD,
Dong Hyuck Nam, MD, Chul Min Ahn, MD, Boyoung Joung, MD and Namsik Chung, MD
Cardiology Division, Yonsei University College of Medicine, Seoul, Korea
CASE REPORT J Cardiovasc Ultrasound  2007;15(2):43-45
We report a case of a 21-year-old male who died from lethal Aspergillus endocarditis 3 months after heart transplantation.
He underwent heart transplantation in other country. He was treated with hemodialysis for acute renal failure due to
cyclosporine and then transferred to our hospital. When he complained high fever, follow-up echocardiography showed
a large mobile echogenic mass attached to posterior mitral valve leaflet. The result of serum Aspergillus galactomannan
antigen assay was positive. He was empirically treated with intravenous amphotericin B and antibiotics. However, he
was rapidly deteriorated and died on hospital day 3.
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(150/100 mmHg). Mid-diastolic heart murmurs (Grade
III/VI) and pansystolic murmurs (Grade IV/VI) at the apex
were audible. There was no ankle edema. Chest radiography
showed mild cardiomegaly and no evidence of pulmonary
edema or pneumonia in both lung fields. Follow-up two
dimensional echocardiography showed a large (3×2 cm
sized) mobile homogenous echogenic mass attached to the
posterior mitral valve leaflet with normal left ventricular
function. Color Doppler echocardiography revealed a large
echogenic mass obstructing mitral valve flow during diastole
as well as mitral regurgitation due to perforation of posterior
mitral leaflet during systole (Fig. 1). Empirical intravenous
antibiotic treatment with meropenem, vancomycin and
amphotericin B was started after sets of blood culture were
drawn. The result of serial blood cultures were negative for
aerobic, anaerobic bacterias and fungi. However, the serum
Aspergillus galactomannan antigen assay showed strong
positive (6.17, cut-off optical density index is 1.5). The blood
trough level of FK506 was 11.2 ng/ml. The patient died of
septic shock with hepatic and renal failure on hospital day 3.
We could not perform autopsy for pathologic confirmation,
because the patient’s family declined.
Discussion
Invasive aspergillosis (IA) is the most common invasive
fungal infection in heart transplant recipients, affecting 1-
14%.2) Aspergillus species can result in a variety of clinical
syndromes, including sinusitis, pneumonia, brain abscess,
endomyocarditis, and disseminated disease in heart transplant
recipient.3) Pulmonary aspergillosis is associated with a mean
mortality rate of approximately 50% in heart transplantation.2)3)
The mortality rate is highest with cerebral aspergillosis (mean
99%), irrespective of the underlying condition. Overall
mortality rate of IA in this population ranges from 53%
to 78%.2)3) Early clinical recognition of this complication
is difficult and laboratory data are not specific or sensitive
enough. Accordingly, antifungal therapy is frequently initiated
too late and some cases are only diagnosed after death. Thus,
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Fig. 1. A: Two dimensional echocardiography showing large (3 x 2 cm sized) mobile homogenous echogenic mass attached at posterior mitral
leaflet (left). Color Doppler echocardiography revealed large echogenic mass obstructing mitral valve flow during diastole (right). B: Continuous wave
Doppler echocardiography showed increased mitral inflow velocity (peak velocity=1.56 m/sec and peak pressure gradient=9.77 mmHg), suggesting of
mitral inflow obstruction. C: Color Doppler echocardiography revealed mitral regurgitation (arrows) due to perforation of posterior mitral leaflet during
systole. D:  M-mode echocardiography showed the mitral orifice is filled with increased echodensity (arrows) representing protruding mass.
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aggressive diagnostic and therapeutic approaches are required
when suggestive lesions are found in high-risk heart transplant
patients such as concomitant CMV disease, re-operation,
and post-transplant hemodialysis.8) Although IA is a serious
disease in heart transplantation, little is known regarding
natural history of this infection due to limited experience.
Several case reports and clinical experiences of invasive
pulmonary aspergillosis were reported.4) Few reports regarding
Aspergillus endocarditis were reported in heart transplant
recipients.5)6)
In this patient, intravenous amphotericin B was empirically
administered within 24 hrs when a large echogenic mass
attached at posterior mitral valve leaflet was found. However,
intravenous amphotericin B may not be sufficient to treat
established fungal foci. Galactomannan, which is released
during growth of hyphae, is a major constituent of Aspergillus
cell walls.7) The serum galactomannan assay by sandwich
enzyme linked immunosorbent assay permits detection of
antigenemia in some patients an average of five to eight days
before the presence of clinical signs, an abnormal chest X-
ray, or positive cultures. The galactomannan assay showed
sensitivity ranges from 61 to 71 percent with a specificity
of 89 to 93 percent for IA.7) Although we did not perform
pathologic diagnosis for aspergillosis, our results strongly
suggested endomyocardial seeding of Aspergillus species.
Surgical removal including valve replacement is the treatment
of choice for Aspergillus endocarditis but would not have
been possible in our patient due to poor clinical conditions.
Recent study reported that post-heart transplant hemodialysis,
cytomegalo virus (CMV) disease, re-operation and other
episodes of aspergillosis in the ward close to the transplantation
date were major risk factors for IA in this population.8) Other
risk factors that have been reported include prolonged
neutropenia, neutrophil function deficits, corticosteroid
therapy, and graft-versus-host disease.9) Singh et al. reported
that patients requiring hemodialysis had a 14% incidence of
IA, and this risk was completely abolished when prophylaxis,
with a lipid preparation of amphotericin B, was administered
during the time renal replacement therapy was required.
However, no impact on the mortality rate was achieved.10)
In this patient, antifungal prophylaxis during hemodialysis
was not done in other country. Sherman-Weber S et al.
reported that S. aureus was the most common pathogen
causing infective endocarditis (40% of post-heart transplant
endocarditis) and followed by Aspergillus fumigatus (30%
of cases).5) Interestringly, Aspergillus fumigatus endocarditis
following heart transplant had antecedent CMV viremia.
This finding suggests that patients with Aspergillus fumigatus
infection had heightened immunosuppression prior to
infective endocarditis.1) The frequent association of CMV
infection with IA has been interpreted as CMV being a
risk factor for invasive fungal disease. Unfortunately, pre-
transplant antibody IgM or IgG for CMV was not examined
and ganciclovir prophylaxis was not given because of impaired
renal function in other country.
In conclusion, this case represents a lethal outcome of
fungal infectious disease following heart transplantation.
Although a prompt approach and aggressive treatment  is
paramount for management of IA, our case shows that
Aspergillus endocarditis has a higher mortality when surgery
would not have been possible in poor clinical condition.
References
1. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N
Engl J Med 1998;338:1741-51.
2. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect
Dis 1996;23:608-15.
3. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. Prevalence and
outcome of invasive fungal infections in 1,963 thoracic organ transplant
recipients. Transplantation 2000;70:112-6.
4. Montoya JG, Chaparro SV, Celis D, Cortes JA, Leung AN, Robbins RC,
Stevens DA. Invasive aspergillosis in the setting of cardiac transplantation.
Clin Infect Dis 2003;37:S281-92.
5. Sherman-Weber S, Axelrod P, Suh B, Rubin S, Beltramo D, Manacchio
J, Furukawa S, Weber T, Eisen H, Samuel R. Infective endocarditis
following orthotopic heart transplantation: 10 cases and a review of the
literature. Transpl Infect Dis 2004;6:165-70.
6. Rueter F, Hirsch HH, Kunz F, Buser P, Habicht JM, Moch H,
Fluckiger U, Zerkowski HR. Late aspergillus fumigatus endomyocarditis
with brain abscess as a lethal complication after heart transplantation. J
Heart Lung Transplant 2002;21;1242-5.
7. Verdaguer V, Walsh TJ, Hope W, Cortez KJ. Galactomannan antigen
detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn
2007;7:21-32.
8. Munoz P, Rodriguez C, Bouza E, Palomo J, Yanez JF, Dominguez MJ,
Desco M. Risk factors of invasive aspergillosis after heart transplantation:
protective role of oral itraconazole prophylaxis. Am J Transpl 2004;4:636-43.
9. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of
asperillus infections in a large cohort of patients undergoing bone marrow
transplantation. J Infect Dis 1997;175:1459-66.
10. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR.
Preemptive prophylaxis with a lipid preparation of amphotericin B for
invasive fungal infections in liver transplant recipients requiring renal
replacement therapy. Transplantation 2001;71:910-913.
